IDH1 and non-small cell lung carcinoma: Even though occurrence of IDH mutations is low in NSCLC, considering the high incidence of this disease and the manifold of developed treatment strategies for IDH-mutated cancers emphasizes the importance of further research in this field (Golub et al. 2019; Rodriguez et al. 2020; Toth et al. 2018).